A detailed history of Balasa Dinverno & Foltz LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Balasa Dinverno & Foltz LLC holds 3,288 shares of MRNA stock, worth $132,407. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,288
Previous 3,225 1.95%
Holding current value
$132,407
Previous $461,000 15.62%
% of portfolio
0.02%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 25, 2022

BUY
$118.07 - $194.18 $7,438 - $12,233
63 Added 1.95%
3,288 $389,000
Q2 2022

Aug 09, 2022

BUY
$117.13 - $176.59 $197,481 - $297,730
1,686 Added 109.55%
3,225 $461,000
Q1 2022

Apr 25, 2022

SELL
$126.46 - $235.05 $40,467 - $75,216
-320 Reduced 17.21%
1,539 $265,000
Q4 2021

Jan 26, 2022

BUY
$225.82 - $368.51 $67,520 - $110,184
299 Added 19.17%
1,859 $472,000
Q3 2021

Oct 26, 2021

BUY
$221.9 - $484.47 $346,164 - $755,773
1,560 New
1,560 $600,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $15.8B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Balasa Dinverno & Foltz LLC Portfolio

Follow Balasa Dinverno & Foltz LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balasa Dinverno & Foltz LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balasa Dinverno & Foltz LLC with notifications on news.